CG
TXMD icon

Cutler Group’s TherapeuticsMD TXMD Stock Holding History

Cutler Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-46
Closed -$1K – 4607
2018
Q3 		$1K Hold
46
– – ﹤0.01% 3885
2018
Q2 		$1K Sell
46
-176
-79% -$53.8K ﹤0.01% 3961
2018
Q1 		$3K Sell
222
-304
-58% -$85.3K ﹤0.01% 3628
2017
Q4 		$12K Sell
526
-1,536
-74% -$428K ﹤0.01% 2998
2017
Q3 		$83K Buy
2,062
+1,602
+348% +$463K ﹤0.01% 1821
2017
Q2 		$11K Sell
460
-2,864
-86% -$717K ﹤0.01% 4092
2017
Q1 		$160K Sell
3,324
-46
-1% -$14.2K 0.01% 1363
2016
Q4 		$29K Buy
3,370
+2,826
+519% +$876K ﹤0.01% 3097
2016
Q3 		$6K Buy
544
+182
+50% +$66.5K ﹤0.01% 4810
2016
Q2 		$6K Buy
+362
New +$149K ﹤0.01% 4784
2016
Q1 		– Sell
-806
Closed -$90K – 7221
2015
Q4 		$90K Buy
+806
New +$298K 0.01% 1889

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's TXMD Position: Q3 2023 in Review

Cutler Group sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 100 shares.

Cutler Group first reported a position in TXMD in Q4 2015 and held it in 16 quarters. The position peaked at $260K in Q2 2017. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Cutler Group reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 100 TherapeuticsMD shares in Q3 2023.
  • Cutler Group first reported a position in TherapeuticsMD in Q4 2015 and held it in 16 quarters.
  • Cutler Group's TherapeuticsMD position peaked at $260K in Q2 2017.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.